NASDAQ:PRAH - PRA Health Sciences Stock Price, Forecast & News

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings results on Thursday, February, 20th. The medical research company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.22. The medical research company earned $800.24 million during the quarter, compared to analysts' expectations of $794.91 million. PRA Health Sciences had a net margin of 7.93% and a return on equity of 28.62%. The company's revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.31 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of $5.77-5.97 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.81. The company issued revenue guidance of $3.23-3.36 billion, compared to the consensus revenue estimate of $3.32 billion.

10 equities research analysts have issued twelve-month target prices for PRA Health Sciences' stock. Their forecasts range from $100.00 to $128.00. On average, they anticipate PRA Health Sciences' share price to reach $117.11 in the next year. This suggests a possible upside of 9.4% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

News stories about PRAH stock have trended very negative on Sunday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for PRA Health Sciences.

PRA Health Sciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,460,000 shares, an increase of 17.7% from the January 15th total of 2,090,000 shares. Based on an average daily trading volume, of 523,200 shares, the days-to-cover ratio is currently 4.7 days. Currently, 3.9% of the company's stock are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), STARPHARMA HOLD/S (SPHRY) and Auxly Cannabis Group (CBWTF).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Paypal (PYPL), Applied Materials (AMAT), Veeva Systems (VEEV), Lam Research (LRCX), Walt Disney (DIS), Arista Networks (ANET) and Netflix (NFLX).

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (4.07%), Janus Henderson Group PLC (3.10%), Massachusetts Financial Services Co. MA (2.70%), State Street Corp (2.27%), Pendal Group Ltd (1.52%) and Standard Life Aberdeen plc (1.23%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Bank of New York Mellon Corp, AQR Capital Management LLC, Pictet Asset Management Ltd., Capital Research Global Investors, Artemis Investment Management LLP, Acadian Asset Management LLC and Strs Ohio. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Janus Henderson Group PLC, Captrust Financial Advisors, FMR LLC, Goldman Sachs Group Inc., Mackay Shields LLC, Assenagon Asset Management S.A. and Franklin Resources Inc.. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $107.09.

PRA Health Sciences has a market capitalization of $6.77 billion and generates $3.07 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]